about
Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisitedAntibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Occurrence of atypical HUS associated with influenza B.The resurgence of mumps and pertussisImmunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey.Influenza and pertussis vaccination coverage in pregnant women.Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.Long-term persistence of antibodies after one or two doses of MMR-vaccine.Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium.CAREGIVERS’ WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTSCommon attitudes about concomitant vaccine injections for infants and adolescents in Flanders, BelgiumReflecting on added values of vaccination in Europe: theory and practice[Prevalence of alcohol abuse and alcohol dependence according to DSM-IV criteria in first year university students]The value of CAGE, CUGE, and AUDIT in screening for alcohol abuse and dependence among college freshmenImplementation of adolescent vaccination programmes through schoolOutbreak of mumps in a vaccinated child population: a question of vaccine failure?Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groupsVaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinantsAdministration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccineMumps outbreaks in highly vaccinated populations: What makes good even better?Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine
P50
Q24817173-96F40815-A98A-457A-AA61-10B6F13F3DECQ30394896-668F9524-4CF3-414A-9D8E-5C734B0C6384Q33438621-8A8C1CAB-9CFE-4BA5-95BB-78CE81C0B257Q37130711-DF0A991C-6A93-4AC3-AC2C-657D35AB95A6Q37850534-0F697FAF-33F1-4CD7-8A3D-1B7DF596F068Q38665422-ED451108-1FF9-408C-9292-BABB04545222Q40209912-C4586886-BC32-46EF-87D2-BAE4B5025E32Q41183853-3D90C302-0CEF-40BA-9440-DB357701CBC7Q41526557-17FB665B-7C25-4463-8075-02E3854264B8Q43885764-953ACF11-0D00-4246-9EDA-5EF3E82CC086Q44660034-37BE9FB7-A121-434F-A0F8-9395B03CF3ADQ49057993-B837F523-99FF-4409-8752-27E952554237Q49125030-8E8A87CB-ABC8-4659-8CDE-D14BCB7AB7FDQ49206733-642E64AA-C6D8-4FF5-81EA-9328BDAA148CQ51751564-9AACABB2-A1E9-4BF3-A181-41915CB6E8DCQ51830889-7BECC27E-2D4F-4A0E-A509-FA34C9825E06Q56880818-AACBEE99-E63D-461A-8F04-E511D14198F4Q56880821-F58FE988-8D39-4ED9-904F-3839A57EBA2FQ73337542-F746B126-6887-4526-844D-89FD9F1072B3Q73350304-EEA734E0-04EA-4CA5-9E25-8C41900A3A41Q73403497-60FE3739-9C54-4F0A-894D-89E5A3F8279FQ73542136-C4C59FDE-7D8F-4626-9106-02F4DBD8F04EQ80322077-8F3E4E3F-E05B-4A9C-84EF-AC1B8CAC346CQ80514472-C9759C33-1242-4E8F-93CB-A73BD9B944DCQ80796989-AF08527F-B2B3-4D2E-BC5A-595EA66DDC23Q81373856-EB305A65-57C7-488E-8FA7-607FB84F810BQ83463077-9A564D45-7517-4D50-9317-3776E96F056AQ91566045-58E06316-9037-4AC4-A2CA-D6F3D1EE524E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Corinne Vandermeulen
@ast
Corinne Vandermeulen
@en
Corinne Vandermeulen
@es
Corinne Vandermeulen
@nl
Corinne Vandermeulen
@sl
type
label
Corinne Vandermeulen
@ast
Corinne Vandermeulen
@en
Corinne Vandermeulen
@es
Corinne Vandermeulen
@nl
Corinne Vandermeulen
@sl
prefLabel
Corinne Vandermeulen
@ast
Corinne Vandermeulen
@en
Corinne Vandermeulen
@es
Corinne Vandermeulen
@nl
Corinne Vandermeulen
@sl
P1053
V-4592-2017
P106
P1153
16640646700
P21
P31
P3829
P3835
corinne-vandermeulen
P496
0000-0002-1954-7554